S. Bondarde

发表

Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients.

D. Doval, S. Nag, G. Bhattacharyya, 2009 .

Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel.

N. Bascomb, G. Bhattacharyya, K. Babu, 2015 .

Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India

G. Bhattacharyya, Sanjay Sharma, S. Deo, 2021, South Asian Journal of Cancer.

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.

W. Gradishar, D. Lokanatha, V. Raina, 2013, European journal of cancer.

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

T. Kolevska, P. Philip, H. Lenz, 2017, Cancer Chemotherapy and Pharmacology.

Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care

D. Doval, H. Malhotra, P. Parikh, 2017 .

Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

D. Doval, D. Lokanatha, P. Julka, 2010 .

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

A. Khorana, E. Gallardo, E. Macias, 2018, Journal of thrombosis and haemostasis : JTH.

Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study

Ravi Kumar, S. Bondarde, S. Patil, 2016, Breast Cancer Research and Treatment.

Study of Risk Factors and Clinical Profile of Stroke in Young Adults

S. Bondarde, Yogesh Jadhav, 2015 .

Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study

S. Babu, Sudeep Gupta, S. Bondarde, 2021, Breast.

Nail changes due to chemotherapy: a prospective observational study of 129 patients

S. Bondarde, V. Zawar, S. Sankalecha, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy

D. Doval, J. Biswas, S. Rajappa, 2017, South Asian Journal of Cancer.

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Y. Hotko, K. Syrigos, M. Gumus, 2021, BioDrugs.

Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group

M. Chandy, V. Radhakrishnan, R. Nair, 2018, Indian Journal of Hematology and Blood Transfusion.

Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey

D. Doval, R. Chacko, K. Prabhash, 2018, South Asian Journal of Cancer.

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

W. Gradishar, D. Lokanatha, V. Raina, 2009 .

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Jing Zhu, Ying Cheng, Yi-long Wu, 2022, Targeted Oncology.

Abstract P2-16-03: Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial

D. Lokanatha, V. Raina, V. Kaklamani, 2010 .

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

Yuehua Wu, X. Liu, Jian-hua Chang, 2017 .

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.